Surface antimicrobial and anti-inflammatory pharmacology

Therapeutic management of corneal and ocular surface pathology requires an understanding of ocular pharmacokinetics, barrier dynamics, formulation chemistry, and regenerative biotechnology. The corneal epithelium acts as a lipophilic barrier through tight intercellular junctions (zonula occludens), while the underlying stroma represents a hydrophilic, lamellar collagenous environment. Effective topically applied pharmacotherapies must balance lipid and water solubility to achieve adequate bioavailability within target tissues.

1. Ophthalmic Antimicrobial Pharmacokinetics & Formulations

Topical Fluoroquinolones

Fluoroquinolones are synthetic, broad-spectrum, bactericidal antibiotics displaying concentration-dependent killing. They inhibit two essential bacterial type II topoisomerase enzymes:

1. DNA Gyrase (Topoisomerase II): Responsible for introducing negative supercoils into bacterial DNA; primarily targeted in Gram-negative bacteria.
2. Topoisomerase IV: Responsible for unlinking and decatenating daughter DNA chromosomes during cell division; primarily targeted in Gram-positive bacteria.

• Second-Generation (Ciprofloxacin 0.3%, Ofloxacin 0.3%): Excellent Gram-negative coverage, but limited Gram-positive coverage. Ciprofloxacin eye drops frequently produce white crystalline precipitates of drug within the base of epithelial defects, which can retard healing.
• Third-Generation (Levofloxacin 0.5%–1.5%): Pure S-(-) enantiomer of ofloxacin, offering doubled potency and improved aqueous solubility.
• Later fluoroquinolones such as moxifloxacin and gatifloxacin inhibit gyrase and topoisomerase IV. Resistance may involve target mutations, efflux and other mechanisms; dual targeting does not make resistance impossible or require precisely two concurrent mutations.

Fortified Preparations and Medication Safety

Severe keratitis may require fortified antibiotics according to organism, local resistance and clinical response. Fluoroquinolone monotherapy and combination fortified therapy are selected by examination and local protocol, rather than a universal size rule. Culture when indicated without delaying treatment. Vancomycin targets Gram-positive organisms; ceftazidime covers susceptible Gram-negative organisms; aminoglycosides act at the 30S ribosome. Prolonged topical treatment can itself delay epithelial healing.

Compounding must use a validated pharmacy formulation, final volume, sterility process and assigned beyond-use date. Adding 80 mg to a bottle already containing 15 mg does not define the final concentration without knowing the added volume. Do not derive a bedside preparation or storage interval from an antibiotic's name alone. Verify label, concentration, route and expiry at each handover.

---

2. Antifungal & Antiviral Pharmacotherapeutics

Antifungal Agents

Fungi possess rigid cell walls rich in chitin and glucan, encasing cell membranes where the dominant sterol is ergosterol (distinct from mammalian cholesterol).

1. Polyenes:
   • Natamycin 5% Ophthalmic Suspension: A tetraene polyene that binds irreversibly to fungal cell membrane ergosterol, disrupting membrane-associated functions; pore formation should not be assumed identical to amphotericin B. Because of its high molecular weight ($665.7\text{ g/mol}$) and poor water solubility, natamycin remains suspended on the ocular surface with limited deep stromal penetration. It is the evidence-based first-line agent for filamentous fungal keratitis (Fusarium and Aspergillus species), as demonstrated by the landmark Mycotic Ulcer Treatment Trial I (MUTT I).
   • Amphotericin B: A polyene used in selected fungal keratitis, particularly yeast disease. Topical preparations require validated pharmacy compounding, formulation compatibility and an appropriate concentration. Do not extrapolate an intravenous reconstitution instruction into a universal topical recipe. Epithelial toxicity and the organism response require monitoring; it is not a blanket preferred treatment for every Aspergillus infection.
2. Triazoles (Voriconazole 1%, Posaconazole):
   • Synthetic triazoles that competitively inhibit the fungal cytochrome P450 enzyme lanosterol 14-$\alpha$-demethylase, halting the conversion of lanosterol to ergosterol. Reconstituted topical Voriconazole 1% (from IV Vfend) exhibits exceptional corneal stromal penetration and enters the anterior chamber readily. MUTT I favoured topical natamycin over topical voriconazole for filamentous ulcers, particularly Fusarium. MUTT II found no overall benefit from adding oral voriconazole for severe filamentous keratitis and more systemic adverse effects. Species, depth and scleral/intraocular extension may justify specialist-selected additional therapy; deep disease alone is not a routine oral-voriconazole indication.

Antiviral Agents

• Ganciclovir 0.15% Ophthalmic Gel (Virgan): A selective acyclic guanosine nucleoside analogue. Monophosphorylated by viral-encoded thymidine kinase, it is subsequently converted by host cellular kinases into ganciclovir triphosphate, which acts as a competitive inhibitor of viral DNA polymerase. Far less toxic to human corneal epithelial cells than older agents (such as trifluridine 1%), ganciclovir is the first-line topical agent for HSV epithelial keratitis (instilled 5 times daily until re-epithelialisation, then 3 times daily for 7 days).
• Trifluridine 1% Drops (F3T): Historical non-selective thymidine analogue incorporated into both viral and human host DNA. Induces severe toxic punctate keratopathy, lacrimal punctal stenosis, and subepithelial scarring; used in some jurisdictions, with epithelial toxicity limiting prolonged treatment.
• Systemic Nucleoside Analogues (Aciclovir & Valaciclovir):
  • Oral Aciclovir: 400 mg 5 times daily for acute HSV epithelial keratitis; 800 mg 5 times daily for Herpes Zoster Ophthalmicus (HZO); 400 mg twice daily for long-term suppressive prophylaxis (HEDS II trial).
  • Oral Valaciclovir: L-valyl ester prodrug of aciclovir converted by first-pass intestinal/hepatic esterases, yielding 3- to 5-fold higher oral bioavailability (54% vs 15% for aciclovir). Dosing: 500 mg twice daily for HSV; 1000 mg three times daily for HZO.

---

3. Topical Anti-Inflammatory & Immunomodulatory Therapeutics

Topical Corticosteroids & The "Soft Steroid" Chemistry

Topical corticosteroids suppress anterior segment inflammation by binding intracellular glucocorticoid receptors, upregulating lipocortin-1 (annexin A1), inhibiting phospholipase $A_2$, and blocking the release of arachidonic acid, leukotrienes, and prostaglandins.

• Potency & Penetration: Prednisolone acetate 1% (lipophilic acetate formulation penetrates intact epithelium readily, making it the gold standard for stromal inflammation) vs Dexamethasone sodium phosphate 0.1% (hydrophilic, penetrates poorly across intact lipophilic epithelium).
• Adverse Effects: Posterior subcapsular cataract, secondary opportunistic infection, exacerbation of herpetic keratitis, corneal stromal melting (via upregulation of matrix metalloproteinases), and corticosteroid-induced ocular hypertension (steroid response).
• Mechanism of Steroid-Induced IOP Spikes: Corticosteroids alter trabecular meshwork (TM) endothelial cells by inhibiting lysosomal enzyme degradation, inducing excess extracellular matrix (GAG) deposition, reorganising the F-actin cytoskeleton into cross-linked actin networks (CLANs), and upregulating myocilin (TIGR protein) expression, leading to increased aqueous outflow resistance in approximately $30–35\%$ of the general population ("steroid responders").

Loteprednol and Pressure Monitoring

Loteprednol is designed for local metabolism to less active products. Clinical studies report a lower propensity for pressure elevation than some other topical steroids, but pressure response, infection and cataract remain possible. Select potency and formulation by the disease and target tissue, then reassess effect and adverse events. A lower-risk steroid is not necessarily adequate for severe intraocular inflammation, and normal pressure before treatment does not exclude a later steroid response.

Topical Calcineurin Inhibitors

1. Ciclosporin A (0.05% emulsion [Restasis], 0.1% cationic emulsion [Ikervis]):
   • Forms an intracellular complex with cyclophilin.
   • The drug-cyclophilin complex binds and inhibits calcineurin phosphatase, preventing the dephosphorylation and nuclear translocation of Nuclear Factor of Activated T-cells (NFAT).
   • Blocks transcription of IL-2, arresting helper T-cell ($CD4^+$) activation and clonal proliferation.
   • Downregulates ocular surface inflammation, preserves conjunctival goblet cells, and increases physiological tear film volume in dry eye disease and graft-versus-host disease (GvHD).
2. Tacrolimus (FK506, 0.03%–0.1% ointment / compounded drops):
   • Binds intracellular FK506-binding protein-12 (FKBP-12), inhibiting calcineurin with $50\text{ to }100\text{ times}$ greater potency than ciclosporin.
   • Highly effective as a steroid-sparing agent in severe vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and high-risk corneal graft rejection prophylaxis.

LFA-1 Antagonist: Lifitegrast 5%

Lifitegrast 5% Ophthalmic Solution (Xiidra) is a small-molecule integrin antagonist designed to block the interaction between:

• Lymphocyte Function-Associated Antigen-1 (LFA-1, CD11a/CD18) expressed on T-lymphocyte cell surfaces, and
• Intercellular Adhesion Molecule-1 (ICAM-1, CD54) overexpressed on inflamed corneal and conjunctival epithelial and vascular endothelial cells.

By blocking this ligand-receptor interaction, lifitegrast inhibits T-cell rolling, extravasation, migration to the ocular surface, and subsequent release of Th1/Th17 inflammatory cytokines (IL-1, TNF-$\alpha$, IFN-$\gamma$).

---